Thereafter, patients enrolled in an open-label extension phase in which 40 mg of Trudexa was administered every other week up to 60 months. lP
jatkovaiheeseen, jossa Trudexaa annettiin 40 mg joka toinen viikko 60 kuukauden ajan.